Evolving therapies for atopic dermatitis: Bridging guidelines and practice

Abstract

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition characterised by dysregulated type 2 immune responses, skin barrier dysfunction and intense pruritus (itching). The disease burden of AD is substantial, affecting at least 171 million individuals worldwide in 2019, representing 2.23% of the global population.1 Among skin diseases, AD ranks highest in disease burden, as measured by disability-adjusted life-years (DALYs).2 Its profound impact on patients’ quality of life, along with significant economic burdens, underscores its status as a major healthcare challenge.